March 31st 2023
In honor of Traumatic Brain Injury Month, held on March 2023, get caught up on some of the latest news in traumatic brain injury as the NeurologyLive® team shares some of our data updates.
March 31st 2023
March 30th 2023
Treatment Advancements to Overcome Barriers in the Management of Schizophrenia: Key Considerations for Pharmacists
1.5 Credit / Neurology, Psychiatry
Novel Treatment Approaches for Alzheimer Disease: Considerations for Pharmacists Across Care Settings
1.5 Credits / Neurology
Seizure Clusters: A Review of New Drug Delivery Methods and Emerging Therapy Options
0.50 Credit / Neurology
Novel Non-stimulant ADHD Treatments: A Review for Pharmacists
0.75 Credit / Neurology, Psychiatry
Treatment of Duchenne Muscular Dystrophy: Updates in Disease-Modifying Drugs
0.75 Credit / Neurology
Therapeutic Strategies for Bipolar Disorder: Recognizing the Intricacies in Disease Management and Considerations for Pharmacists Across Practice Settings
2.0 Credits / Neurology, Psychiatry
Strategies to Improve the Management of Migraine: Clinical Updates for Pharmacists and Patient-Case Review
1.0 Credit / Neurology
Recognizing Rett Syndrome: Managed Care Insights on Disease Burden
1.5 Credits / Neurology, Rare Diseases
Blarcamesine Deemed Safe, Effective in Phase 2 Extension Study of Parkinson Disease DementiaMarch 30th 2023
Despite a pause in the trial due to the COVID-19 pandemic, patients who opted to continue treatment into the open-label extension demonstrated significant improvements in Parkinson disease dementia symptoms for up to 48 weeks.
Mazindol Extended Release Agent Demonstrates Significant Efficacy in Open-Label Extension in NarcolepsyMarch 30th 2023
Over a 6-month open-label extension period, mazindol ER was found to be safe, with patients demonstrating significant decreases in number of weekly cataplexy episodes and improvements in daytime sleepiness.
Tiziana Announces Planned Phase 2 Study of Foralumab in Progressive Multiple SclerosisMarch 29th 2023
Foralumab, a fully human anti-CD3 monoclonal antibody, has had treatment effect demonstrated in patients with COVID-19 and with multiple sclerosis, as well as in healthy normal individuals.
Differences in Diagnosis and Prevention Between NMOSD and MSMarch 29th 2023
Michael Levy, MD, PhD, associate professor at Harvard Medical School, talked about the differences between multiple sclerosis and neuromyelitis optica spectrum disorder, the currently available treatments, and next steps in research.
NeuroVoices: Orrin Devinsky, MD, on Metabolic Changes and Benefits of Modified Atkins Diet in Epilepsy SurgeryMarch 29th 2023
The director of the Comprehensive Epilepsy Center at NYU Langone provided perspective on the advantages modified Atkins diets bring to patients with epilepsy and those considering epilepsy surgery.
Avadel Pharmaceuticals Urges FDA to Make Decision on Extended-Release Formulation of Sodium OxybateMarch 28th 2023
In a phase 3 study, extended-release sodium oxybate demonstrated statistically significant and clinically meaningful results in excessive daytime sleepiness, clinician’s assessment of patient’s functioning, and reduction in cataplexy attacks.
Aminoacyl-tRNA Synthetase-Interacting Multifunctional Protein-1 Shows Promise as Predictor for Severity of Acute AQP4-IgG NMOSDMarch 28th 2023
Disease activity, severity, or effect of treatment in patients with NMOSD may be predicted by aminoacyl-tRNA synthetase-interacting multifunctional protein-1.
Sodium Oxybate Demonstrates Long-term Safety and Maintained Efficacy in Pediatric Narcolepsy with CataplexyMarch 28th 2023
An evaluation on the long-term treatment profile of sodium oxybate on pediatrics with narcolepsy revealed a safety profile similar to previous adult studies and identified no unexpected safety concerns.
Milestone-Free Time Longer in IV Edaravone-Treated Patients With ALS, Administrative Claims SuggestMarch 27th 2023
Time to milestones such as invasive and noninvasive ventilation, speech-generating devices, and hospice care took significantly longer while on intravenous edaravone.
New Analysis of Phase 3 Clarity AD Study Highlights Health and Economic Benefits From LecanemabMarch 27th 2023
At the willingness to pay threshold of $200,000 per QALY gained, the estimated annual value for lecanemab was $35,678 and $37,351 from the payer and societal perspectives, respectively.
BrainStorm Announces FDA AdComm Meeting for NurOwn Stromal Cell TherapyMarch 27th 2023
NurOwn, an autologous mesenchymal stromal cell approach for ALS, failed to meet its primary end point in a pivotal phase 3 trial, but showed promising results on less severe forms of the disease in subsequent analyses.
NeurologyLive® Brain Games: March 26, 2023
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Muscular Dystrophy Association (MDA).
SYMBYX Neuro Light Therapy Wellness Helmet Positively Impacts Parkinson Disease SymptomsMarch 25th 2023
Over a 12-week treatment period, patients with Parkinson disease on light therapy demonstrated statistically significant improvements of 58% and 40% in lower and upper limb coordination and movement.
Depression History Shows No Impact on Efficacy, Safety of Solriamfetol in Treating Obstructive Sleep Apnea, NarcolepsyMarch 24th 2023
Results of solriamfetol were similar when outcomes were examined in subgroups of concomitant antidepressant use, regardless of depression history, indicating that antidepressants did not affect the efficacy of the drug.
Losmapimod Demonstrates Significant Slowing of Facioscapulohumeral Muscular Dystrophy Over Long-Term PeriodMarch 23rd 2023
Durability of treatment response on reachable workspace was observed among those who continued losmapimod throughout the 96-week period and those who switched from placebo.
Myasthenia Agent Zilucoplan Continues to Show Positive Efficacy in Long-Term ExtensionMarch 23rd 2023
In participants who received placebo during the parent studies, rapid improvements were observed as early as week 1 after switching to zilucoplan, and continued through week 12 of the extension period.